91444-19-8

Upstream product

• 62655-56-5 2-(4'-methoxy-phenyl)-6-methoxy-indole 
• 75-03-6 ethyl iodide 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 536-90-3 m-Anisidine 

Downstream Products

• 158611-26-8 3-Acetyl-1-ethyl-6-methoxy-2-(4-methoxyphenyl)-indol 
• 86111-20-8 Acetic acid 2-(4-acetoxy-phenyl)-1-ethyl-1H-indol-6-yl ester 
• 158611-39-3 2-(1-Ethyl-6-methoxy-2-(4-methoxyphenyl)-indol-3-yl)-nitroethen 
• 158611-45-1 <1-Ethyl-6-hydroxy-2-(4-hydroxyphenyl)-indol-3-yl>-methylidenmalonsaeuredinitril 
• 158611-41-7 2-(1-Ethyl-6-hydroxy-2-(4-hydroxyphenyl)-indol-3-yl)-nitroethen 
• 157977-25-8 2-(1-Ethyl-6-hydroxy-2-(4-hydroxyphenyl)-indol-3-yl)-1,3-dinitropropan 
• 157977-23-6 1-Ethyl-6-hydroxy-2-(4-hydroxyphenyl)-indol-3-carbaldehyd 
• 157977-27-0 1-Ethyl-6-methoxy-2-(4-methoxyphenyl)-indol-3-carbaldehyd 
• 86111-05-9 1-Ethyl-2-(4-hydroxy-phenyl)-1H-indol-6-ol 

Relevant academic research and scientific papers

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods for treating resistant tumors

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

Methods of treating nueropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

HETEROCYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS

This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein. Another embodiment of this invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

1,3-Dinitropropanes: Intermediates to 1,3-diaminopropanes

Reduction of malodinitriles 4 and 10 to the corresponding diamines does not work. - Reduction of dinitro-2-(indol-3-yl)-propanes 13 and 16 and subsequent reaction with K2PtCl4 afford the corresponding dichloroplatinum(II) complexes 14 and 17. Complexes 17 show weak binding affinities to the estrogen receptor and no antitumor activity towards MCF-7 and MDA-MB-2231-cell lines. - Twofold addition of nitromethane to aldehyde 24 is possible.

3-Substituted 2-phenylindoles: Synthesis and biological properties

Knoevenagel-reaction of indol-3-carbaldehydes 5a,b and 7a,b with nitromethane leads to the nitroethenes 12 and 14, the analogous reaction with malodinitrile to the methylidenemalonic acid dinitriles 16.- Michael-addition of nitromethane at 12 and 14 affor

2-Phenylindoles. Relationship between Structure, Estrogen Receptor Affinity, and Mammary Tumor Inhibiting Activity in the Rat

A number of 2-phenylindole derivatives with one hydroxy group in the meta or para position of the phenyl ring and a second one in position 5, 6, or 7 of the indole nucleus were synthesized.In addition, different alkyl groups were introduced into positions